Anti-tumor effect of human lymphocytes and interleukin-2.
We studied the anti-tumor effect of control human lymphocytes and interleukin-2 (IL-2) activated lymphocytes (lymphokine activated killer cells, LAK-cells), on two different cell lines: SW742 human colon adenocarcinoma and K562 human myeloid leukaemia cell line. Our results indicate that IL-2 augment the anti-tumor activity of human lymphocytes and these LAK-cells lyse the tumor cells very efficiently. Furthermore, we treated the target cells (SW742 and K562) with different cytokines in order to establish whether these cytokines have any effect on susceptibility to lysis by LAK-cells. Anti-tumor activity of human lymphocytes and IL-2 is discussed in this study.
Anwer
F
F
Al Hada Armed Forces Hospital, Taif, Saudi Arabia.
Mesri
M
M
Rees
R C
RC
Kazmi
S U
SU
D000230:Adenocarcinoma / Q000276:immunology* / Q000628:therapy; D000818:Animals; D003110:Colonic Neoplasms / Q000276:immunology* / Q000628:therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D066298:In Vitro Techniques; D016898:Interferon-alpha / Q000008:administration & dosage; D007375:Interleukin-1 / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage / Q000276:immunology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000628:therapy; D008214:Lymphocytes / Q000276:immunology*; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage
D016898:Interferon-alpha; D007375:Interleukin-1; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha